Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Kaken Pharmaceutical CoKKPCF 69 Current Ratio is 4.52 as of Mar. 2026, which is 5% below its 10-year median of 4.76. GuruFocus rates KKPCF with a GF Score™ of 69/100 and a GF Value™ of $25.42. The stock has 2 warning signs investors should review. Among 998 Drug Manufacturers companies, Kaken Pharmaceutical Co ranks better than 82.46% on this metric.
The current ratio is a liquidity ratio that measures a company's ability to pay short-term obligations. It is calculated as a company's Total Current Assets divides by its Total Current Liabilities. Kaken Pharmaceutical Co's current ratio for the quarter that ended in Mar. 2026 was 4.52.
Kaken Pharmaceutical Co has a current ratio of 4.52. It indicates the company may not be efficiently using its current assets or its short-term financing facilities. This may also indicate problems in working capital management.
The historical rank and industry rank for Kaken Pharmaceutical Co's Current Ratio or its related term are showing as below:
KKPCF'
s Current Ratio Range Over the Past 10 Years
Min: 3.31 Med: 4.76 Max: 5.81
Current: 4.52
During the past 13 years, Kaken Pharmaceutical Co's highest Current Ratio was 5.81. The lowest was 3.31. And the median was 4.76.
KKPCF's Current Ratio is ranked better than 82.46% of 998
companies
in the Drug Manufacturers industry
Industry Median: 2
vs KKPCF: 4.52
Kaken Pharmaceutical Co (OTCPK:KKPCF) Current Ratio Explanation
The current ratio can give a sense of the efficiency of a company's operating cycle or its ability to turn its product into cash. Companies that have trouble getting paid on their receivables or have long inventory turnover can run into liquidity problems because they are unable to alleviate their obligations. Because business operations differ in each industry, it is always more useful to compare companies within the same industry.
Acceptable current ratios vary from industry to industry and are generally between 1 and 3 for healthy businesses.
The higher the current ratio, the more capable the company is of paying its obligations. A ratio under 1 suggests that the company would be unable to pay off its obligations if they came due at that point. While this shows the company is not in good financial health, it does not necessarily mean that it will go bankrupt - as there are many ways to access financing - but it is definitely not a good sign.
If all other things were equal, a creditor, who is expecting to be paid in the next 12 months, would consider a high current ratio to be better than a low current ratio, because a high current ratio means that the company is more likely to meet its liabilities which fall due in the next 12 months.
Kaken Pharmaceutical Co Current Ratio Related Terms
Kaken Pharmaceutical Co Current Ratio Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Drug Manufacturers - Specialty & Generic subindustry, Kaken Pharmaceutical Co's Current Ratio, along with its competitors' market caps and Current Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Kaken Pharmaceutical Co Current Ratio vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Kaken Pharmaceutical Co's Current Ratio distribution charts can be found below:
* The bar in red indicates where Kaken Pharmaceutical Co's Current Ratio falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Kaken Pharmaceutical Co (KKPCF) has a Current Ratio of 4.52 as of Mar. 2026. This is near median its historical median of 4.76. Over the past decade, Kaken Pharmaceutical Co's Current Ratio has ranged from 3.31 to 5.81. According to the industry distribution chart, Kaken Pharmaceutical Co ranks #175 out of 998 companies in the Drug Manufacturers industry, placing it in the top 17.5%.
Is Kaken Pharmaceutical Co's Current Ratio too high?
Kaken Pharmaceutical Co's current Current Ratio of 4.52 is near median its 10-year median of 4.76. Over the past 10 years, this metric has ranged from a low of 3.31 to a high of 5.81. The Drug Manufacturers industry median Current Ratio is 2.00. Kaken Pharmaceutical Co's value of 4.52 is 126% above this industry median. Based on the distribution chart, Kaken Pharmaceutical Co ranks #175 out of 998 companies in the Drug Manufacturers industry, which is in the top quartile — a strong position relative to peers. Overall, Kaken Pharmaceutical Co has a GF Score™ of 69/100, reflecting its overall financial health beyond just this single metric.
How does Kaken Pharmaceutical Co's Current Ratio compare to ZTS and UTHR?
According to the Drug Manufacturers industry distribution chart, Kaken Pharmaceutical Co ranks #175 out of 998 companies for Current Ratio. This places Kaken Pharmaceutical Co in the top 18% of its industry — outperforming the majority of peers. The industry median Current Ratio is 2.00. Kaken Pharmaceutical Co's value of 4.52 is 126% above this benchmark. Historically, Kaken Pharmaceutical Co's own Current Ratio has ranged from 3.31 to 5.81 over the past decade. While the company's 10-year median is 4.76 vs. the industry median of 2.00, Kaken Pharmaceutical Co has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Current Ratio for a Drug Manufacturers company?
The median Current Ratio among Drug Manufacturers companies is 2.00, based on 998 companies in the industry. Companies in the top quartile (top 25%) have a Current Ratio significantly above this median, while those in the bottom quartile fall well below. However, Current Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Kaken Pharmaceutical Co's current Current Ratio of 4.52 is 126% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Current Ratio mean?
A high Current Ratio can signal that a stock is expensive relative to its fundamentals. For the Drug Manufacturers industry, the median Current Ratio is 2.00 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Kaken Pharmaceutical Co's current Current Ratio is 4.52, which is near median its own 10-year median of 4.76. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Kaken Pharmaceutical Co stock overvalued right now?
Kaken Pharmaceutical Co (KKPCF) has a current Current Ratio of 4.52. The stock's GF Value™ is $25.42, compared to a current price of $26.00 — trading 2.3% above its estimated fair value. The current Current Ratio is 4.52, which is near median its 10-year median of 4.76 and 126% above the Drug Manufacturers industry median of 2.00. Kaken Pharmaceutical Co's overall GF Score™ is 69/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Current Ratio calculated?
Current Ratio is calculated from a company's financial statements. For Kaken Pharmaceutical Co (KKPCF), the current Current Ratio is 4.52 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Kaken Pharmaceutical Co (KKPCF) Overvalued in 2026?
Based on GuruFocus' analysis, Kaken Pharmaceutical Co stock appears to be overvalued.
The current stock price of $26.00 is trading 2.3% above its estimated GF Value™ of $25.42.
Key valuation signals for KKPCF:
Current Ratio: 4.52 (near median its 10-year median of 4.76)
GF Value™: $25.42 vs. price of $26.00 (2.3% above fair value)
Industry Position: 126% above the Drug Manufacturers median (#175 of 998)
No single metric tells the full story. See the KKPCF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Kaken Pharmaceutical Co Ltd is a specialty and generic drug manufacturing company. The company organizes its segments between pharmaceutical and real estate activities. The pharmaceutical segment consists of pharmaceutical drugs, medical devices, and agrochemicals. In the real estate segment, the majority of revenue is generated through commercial facility rental fees. Sales in Japan constitute more than 90% of revenue. Kaken considers merger and acquisition investment to be a potential component of its operational growth strategy for expanding its research, development, manufacturing, and marketing capabilities.
69GF Score
Get the complete analysis for KKPCF
Current Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
KKPCF has been successfully added to your 
